Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ER Positive, HER2 Negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT07318805
What this trial is testing

Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Breast CancerMetastatic Breast Cancer (HR+/ HER2-)Colorectal Cancer+2 more
Pfizer 260
Not applicableLooking for participantsNCT07214532
What this trial is testing

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Who this might be right for
Breast NeoplasmsCarcinoma, Ductal, BreastReceptors, Estrogen (for ER-positive Requirement)
Natera, Inc. 725
Not applicableUnknownNCT00897728
What this trial is testing

Study of Tumor and Blood Samples From Women With Breast Cancer

Who this might be right for
Breast Cancer
Institut Curie 180
Testing effectiveness (Phase 2)UnknownNCT04571437
What this trial is testing

Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study)

Who this might be right for
Breast CancerEstrogen Receptor-positive Breast CancerMetastatic Breast Cancer
Cairo University 204
Early research (Phase 1)Study completedNCT03236974
What this trial is testing

Study to Compare the Effects of AZD9496 vs Fulvestrant in Breast Cancer.

Who this might be right for
Postmenopausal Women With ER+ HER2- Primary Breast Cancer
AstraZeneca 49
Testing effectiveness (Phase 2)UnknownNCT03750396
What this trial is testing

Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer

Who this might be right for
Breast CancerRecurrent Breast CancerStereotactic Body Radiotherapy+3 more
Gangnam Severance Hospital 110
Testing effectiveness (Phase 2)UnknownNCT04488107
What this trial is testing

Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c

Who this might be right for
Breast Neoplasms
Ahon Pharmaceutical Co., Ltd. 78
Testing effectiveness (Phase 2)Study completedNCT01441947
What this trial is testing

Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

Who this might be right for
Breast Cancer
Massachusetts General Hospital 68
Testing effectiveness (Phase 2)Study completedNCT01677455
What this trial is testing

An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer

Who this might be right for
Breast CancerHER-2 Positive Breast CancerTriple Negative Breast Cancer+1 more
Synta Pharmaceuticals Corp. 51
Testing effectiveness (Phase 2)Study completedNCT01151046
What this trial is testing

Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer

Who this might be right for
Her2 Negative Breast Cancer Patients
Merrimack Pharmaceuticals 118
Not applicableUnknownNCT05734950
What this trial is testing

Biological Characteristics of Older Women (> 70 Years) With ER Positive, HER2 Negative Early Breast Cancer

Who this might be right for
Breast Cancer Female
Royal Marsden NHS Foundation Trust 100
Testing effectiveness (Phase 2)Study completedNCT01381874
What this trial is testing

Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

Who this might be right for
Metastatic ER+ Her2- Breast CancerPostmenopausal
Janssen Research & Development, LLC 297
Testing effectiveness (Phase 2)Study completedNCT03839823
What this trial is testing

Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 222
Testing effectiveness (Phase 2)Looking for participantsNCT05305924
What this trial is testing

Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer

Who this might be right for
ER-Positive Breast CancerHER2-negative Breast Cancer
The Methodist Hospital Research Institute 28
Large-scale testing (Phase 3)Active Not RecruitingNCT04964934
What this trial is testing

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

Who this might be right for
ER-Positive HER2-Negative Breast Cancer
AstraZeneca 315
Testing effectiveness (Phase 2)Ended earlyNCT00726180
What this trial is testing

Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer

Who this might be right for
Breast Cancer
University of Michigan Rogel Cancer Center 1
Testing effectiveness (Phase 2)Ended earlyNCT03566485
What this trial is testing

Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer

Who this might be right for
Stage III Breast CancerStage IIIA Breast CancerStage IIIB Breast Cancer+4 more
Vanderbilt-Ingram Cancer Center 12
Early research (Phase 1)Study completedNCT01009437
What this trial is testing

Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer

Who this might be right for
Breast Cancer
Masonic Cancer Center, University of Minnesota 28
Not applicableNot Yet RecruitingNCT06882499
What this trial is testing

Stereotactic Ablative Body Radiotherapy (SABR) With Maintenance of Systemic Therapy Versus Physicians' Choice of Systemic Therapy for Oligoprogressive ER-positive, Her-2 Negative Breast Cancer II

Who this might be right for
Breast Cancer, MetastaticMetastatic Breast Cancer
Peter MacCallum Cancer Centre, Australia 74
Not applicableUnknownNCT04247035
What this trial is testing

Τreatment Standards and Outcomes of Patients With ER/PR Positive, HER2-negative Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Hellenic Society of Medical Oncology 300
Next Page